Trials / Completed
CompletedNCT00880568
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study determines recommended clinical dose, to evaluate the safety, tolerability and pharmacokinetics of MK-1496 in patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom no standard therapy exists, in two dosing schedules in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1496 | MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle |
| DRUG | MK-1496 | MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-11-01
- Completion
- 2011-01-01
- First posted
- 2009-04-14
- Last updated
- 2015-02-19
- Results posted
- 2012-10-26
Source: ClinicalTrials.gov record NCT00880568. Inclusion in this directory is not an endorsement.